Thomas Fuller | Soup images | LIGHTROCKET | Getty images
Pfizer Monday said he would buy drugs to lose weight Metsera In an agreement of up to $ 7.3 billion, including future payments, since it fights to win a portion in the booming drug market.
Pfizer said he will pay an initial action of $ 47.50 per cash action for metsera, a premium of almost 43% at the closing price of the Biotechnology Company of $ 33.32. That gives the agreement a business value of $ 4.9 billion.
The PACT also includes a contingent value of up to $ 22.50 per share based on possible clinical and regulatory achievements for metsest medications, which could bring total value to $ 70 per share.
The agreement is expected to close at the end of the year. Metsera shares rose more than 60% in the negotiation prior to the market on Monday, while Pfizer shares increased more than 1%.
The movement occurs after a chain of setbacks for Pfizer in the space of obseity. The pharmaceutical giant struggled to develop his own candidate for the main obesity drug, Danuglipron, before deciding to eliminate it completely in April due to security concerns. Pfizer also suspended a different pill once a day in June 2023 due to high liver enzymes in patients who received it.
Pfizer has drugs of obesity in anterior stage in its pipe that work in different ways, but the company has faced a growing pressure from investors to accelerate its impulse to the market.
The opportunity could be huge. Some analysts expect the drug space to lose weight can be worth approximately $ 100 billion for the 2030s, with space for the new rivals to compete with popular injections of Eli Lilly and Novo Nordisk.
Metsera, founded in 2022, brings a pipe of oral and injectable treatments with different objectives that the company had collected through its own license and acquisition agreements. That includes a GLP-1 medicine called MET-233I, which helped patients lose up to 8.4% of their weight in 36 days in a small early stage trial. Metsera is developing that treatment as an injectable potential once a month, which means that patients can take it less frequently than existing weekly injections.
Metsera pipe also includes a monthly drug aimed at a hormone called amiline, along with two oral GLP-1 candidates “that is expected to begin impending judgments,” Pfizer said in a statement.
“The proposed metsera acquisition is aligned with our focus on directing our investments to the most shocking opportunities and drives Pfizer to this key therapeutic area,” said the CEO of Pfizer, Albert Bourla, in a statement. “We are excited to apply our deep heart experience and commercial infrastructure and commercial infrastructure to accelerate a portfolio that includes the possible best injectable injectables.”
In a note on Monday, the Leadck Partners analyst David Risinger said that the firm estimates that metsest obesity candidates have the potential to generate more than $ 5 billion in combined maximum annual sales. In a separate note on Monday, JPMorgan Analyst Chris Schott said that metsera experimental medications “should accelerate” Pfizer's entry into the market.
Metsera, based in New York, was made public this year in one of the largest biotechnology listings of 2025. It is among several companies that compete to develop next -generation obesity treatments after the success of weekly injections such as the Obesity drug of Eli Lilly Zepbound and the Wegovy rival.
